Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy?

Core Viewpoint - The market anticipates Esperion Therapeutics (ESPR) will report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Esperion is expected to post quarterly earnings of $0.23 per share, reflecting a year-over-year increase of +330% [3]. - Revenues are projected to reach $160.58 million, which is a 132.4% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 58.82% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Esperion is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +37.63% [11]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [9]. - Esperion currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Esperion was expected to post a loss of $0.09 per share but actually reported a loss of -$0.16, resulting in a surprise of -77.78% [12]. - Over the past four quarters, Esperion has beaten consensus EPS estimates two times [13]. Industry Comparison - Another company in the Zacks Medical - Drugs industry, Harrow (HROW), is expected to report earnings of $0.4 per share, indicating a year-over-year change of +60% [17]. - Harrow's consensus EPS estimate has been revised down by 666.7% over the last 30 days, and it currently has an Earnings ESP of -0.42% with a Zacks Rank of 4 (Sell) [18].